2Dopamine: an immune transmitterSarah Thomas Broome，Krystal Louangaphay，Kevin A. Keay，Gian Marco Leggio，Giuseppe Musumeci，Alessandro CastorinaREVIEWS2173-2185
3The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesisAdriana Delice Foster，Sarah Lyn ReaREVIEWS2186-2194
4Mounting evidence of FKBP12 implication in neurodegenerationGabriella Caminati，Piero ProcacciREVIEWS2195-2202
6Medicinal plants and natural products as neuroprotective agents in age-related macular degenerationFrancisco Bosch-Morell，Victoria Villagrasa，Teresa Ortega，Nuria Acero，Dolores Mu?oz-Mingarro，M. Eugenia González-Rosende，Encarna Castillo，M. Amparo Sanahuja，Pilar Soriano，Isabel Martínez-SolísREVIEWS2207-2216
7Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemiaGeorge Zaki Ghali，Michael George Zaki GhaliREVIEWS2217-2234
8Engineering mesenchymal stromal/stem cell-derived extracellular vesicles with improved targeting and therapeutic efficiency for the treatment of central nervous system disordersAlexandra M. Iavorovschi，Aijun WangPERSPECTIVES2235-2236
9Adaptable retinal ganglion cell function: assessing autoregulation of inner retina pathwaysTsung-Han Chou，Vittorio PorciattiPERSPECTIVES2237-2238
10Prion-like domain disease-causing mutations and misregulation of alternative splicing relevance in limb-girdle muscular dystrophy(LGMD) 1GCristina Batlle，Salvador VenturaPERSPECTIVES2239-2240
11Neurotrophin-3-mediated locomotor recovery: a novel therapeutic strategy targeting lumbar neural circuitry after spinal cord injuryQi Han，Xiao-Ming XuPERSPECTIVES2241-2242
12How and why does photobiomodulation change brain activity?John Mitrofanis，Luke A. HendersonPERSPECTIVES2243-2244
13Activation of tyrosine phosphatases in the progression of Alzheimer's diseaseAlexandre F. R. Stewart，Hsiao-Huei ChenPERSPECTIVES2245-2246
14Targeting cannabidiol to specific areas of the brain: an ultrasound-based strategyJacopo Junio Valerio Branca，Donatello Carrino，Alessandra PaciniPERSPECTIVES2247-2248
15Remote ischemic conditioning: the brain's endogenous defense against strokeCaleb J. Heiberger，Tej Mehta，Jae Kim，Divyajot S. SandhuPERSPECTIVES2249-2250
16Targeting the transferrin receptor to develop erythropoietin for Alzheimer's diseaseRachita K. SumbriaPERSPECTIVES2251-2252
17Recent advances on the role of long non-coding RNAs in Alzheimer's diseaseKyle Doxtater，Manish K. Tripathi，Mohammad Moshahid KhanPERSPECTIVES2253-2254
18Whole-brain three-dimensional imaging for quantification of drug targets and treatment effects in mouse models of neurodegenerative diseasesHenrik H. Hansen，Urmas Roostalu，Jacob Hecksher-S?rensenPERSPECTIVES2255-2257
19Activation of β2 adrenergic receptors promotes adult hippocampal neurogenesisValeria Bortolotto，Mariagrazia GrilliPERSPECTIVES2258-2259
20Small molecules to prevent the neurodegeneration caused by α-synuclein aggregationSamuel Pe?a-Díaz，Jordi Pujols，Salvador VenturaPERSPECTIVES2260-2261
